Oprah's Weight Loss Dilemma: The Ozempic

Recent Cochrane reviews commissioned by the World Health Organization show that blockbuster weight loss drugs like Ozempic deliver substantial results. According to ScienceDaily reporting on February 11, these GLP-1 drugs, including semaglutide in Ozempic and tirzepatide in Mounjaro, lead to average weight losses of 11 to 16 percent over one to two years in people with obesity, far outperforming placebos in trials with thousands of participants. Tirzepatide achieved about 16 percent reduction after 12 to 18 months, while semaglutide hit roughly 11 percent after 24 to 68 weeks, with benefits lasting as long as treatment continues. However, most studies were funded by drugmakers, long-term safety data remain limited, and common side effects like nausea affect many users.A Rutgers Health study published this week in the Journal of Medical Internet Research, as reported by Healthline on February 16, reveals that Ozempic users often prioritize weight loss over these side effects. Researchers analyzed online reviews and found that 67 percent reported reduced appetite and cravings alongside weight loss, making them satisfied enough to continue despite gastrointestinal issues in 62 percent of cases. Lead author Abanoub Armanious noted that everyday users value efficacy highly, even tolerating discomfort that prompts some to stop other treatments. Bariatric surgeon Mir Ali added that patients paying out of pocket show strong motivation, often seeking remedies for nausea rather than quitting.Novo Nordisk announced on February 17 that a new clinical study demonstrated people lost about 21 percent of their body weight on average with their obesity treatment, highlighting ongoing advancements in GLP-1 therapies. No fresh comments from Oprah Winfrey on Ozempic emerged this week, though her past support underscores the cultural buzz around these medications.Experts like Juan Franco from Heinrich Heine University emphasize the excitement after decades without effective options, but call for independent long-term studies on heart health, quality of life, and weight regain after stopping. Access issues persist due to high costs, though semaglutide patents expire this year, potentially lowering prices.Thanks for tuning in, listeners, please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Recent news highlights ongoing developments in weight loss treatments like Ozempic, with fresh insights from clinical reviews and patient experiences. On February 11, 2026, Cochrane reviews commissioned by the World Health Organization analyzed GLP-1 drugs including semaglutide, sold as Ozempic and Wegovy. These studies, drawing from dozens of trials with tens of thousands of participants, show semaglutide leads to an average weight loss of about 11 percent after six to 18 months when paired with diet and exercise. Tirzepatide, marketed as Mounjaro and Zepbound, achieved around 16 percent loss in similar periods. Researchers note these benefits persist during treatment but emphasize limited long-term safety data, common side effects like nausea, and heavy industry funding in most trials. Cochrane reports highlight the need for independent studies on heart health, quality of life, and global access, as high costs limit use in lower-income regions.A Rutgers Health study published this week in the Journal of Medical Internet Research examined why Ozempic users stick with it despite side effects. Analyzing online reviews, researchers found perceived effectiveness in curbing appetite and shedding pounds outweighs issues like stomach upset for most. Lead author Abanoub Armanious noted that everyday users prioritize real results over hype from celebrities or social media. Separately, Weill Cornell Medicine researchers reported on February 11 that GLP-1 drugs like tirzepatide may lower risks of diabetic retinopathy progression in diabetes patients, countering earlier concerns.Oprah Winfrey continues to speak openly about her GLP-1 use, as covered in recent AOL articles. The media icon, who lost about 50 pounds starting in 2023 but regained 20 after briefly stopping, now views these medications as a lifelong tool like blood pressure drugs. Promoting her book Enough, Winfrey shared on The View and her podcast that the drugs silenced constant food thoughts, freeing her from self-blame. She told listeners obesity is not a willpower failure but a brain-driven condition, urging others to seek medical options without shame. Winfrey, who covers costs for friends, also noted reduced alcohol cravings as a bonus.Meanwhile, excitement builds around Eli Lillys oral pill orforglipron, an injectable-free alternative to Ozempic. Phase 3 trials like ATTAIN-1 showed 12.4 percent average weight loss over 72 weeks, with many maintaining results after switching from shots. Walk In reports it could launch in Canada soon, offering daily convenience without fasting, though generics of semaglutide arrive mid-2026 for affordability.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Recent research from the University of Cambridge highlights a key concern with popular weight-loss drugs like Ozempic and Wegovy. These medications sharply reduce appetite, leading to calorie intake dropping by sixteen to thirty-nine percent, which drives effective weight loss for people with obesity. However, experts from University College London and the University of Cambridge warn that many users lack proper nutrition guidance, risking muscle loss of up to forty percent of total weight shed and deficiencies in protein, vitamins, and minerals that could cause fatigue, weakened immunity, hair loss, or osteoporosis. Dr. Adrian Brown from UCL stresses integrating nutritional care, such as prioritizing nutrient-dense foods and even protein distribution across meals, drawing from post-bariatric surgery practices to preserve lean mass and support long-term health.Oprah Winfrey has been candid this week about her experience with these GLP-1 drugs, including Ozempic, sharing how they silenced the constant food noise in her brain and helped her lose over fifty pounds since starting in twenty twenty-three, combined with hiking and resistance training. In interviews on The Oprah Podcast and CBS Sunday Morning, the seventy-one-year-old media icon revealed she quit the drug after six months, only to regain twenty pounds despite strict diet and exercise, proving to her it is a lifetime tool, much like blood pressure medication. Oprah described overcoming deep shame from decades of self-blame and public ridicule, now viewing obesity as a clinical disease beyond personal willpower, not a moral failing. She emphasized to People Magazine and on The View that the medications feel like relief and redemption, enabling her to reach one hundred fifty-five pounds and feel in the best shape of her life, while rejecting stigma around using them responsibly alongside lifestyle changes.These insights underscore the drugs transformative impact, though experts urge balanced approaches to avoid pitfalls.Thanks for tuning in, listeners. Please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In the past week, weight loss drugs like Ozempic, Wegovy, and Mounjaro have reshaped global conversations on obesity, marking 2026 as a potential turning point. Firstpost reports that these GLP-1 drugs, originally developed for type two diabetes, trigger significant weight loss by curbing appetite, leading to falling obesity rates in the United States for the first time since the 1980s. One in eight Americans now uses these medications, sparking changes across industries. Supermarkets see snack sales drop by up to 10 percent, with less demand for chips, cookies, and soda, while fresh fruits and vegetables gain popularity. Companies like Nestle launch GLP-1 friendly meals, and restaurants shrink portion sizes. Alcohol consumption dips among users, boosting non-alcoholic drink sales. Retailers face challenges as smaller clothing sizes sell out, leaving billions in unsold larger stock, and gyms adapt with strength training programs to counter muscle loss, which can account for 39 to 40 percent of total weight shed.Oprah Winfrey has been candid about her experiences with these drugs. In recent interviews covered by AOL and Fox News, the 71-year-old media icon revealed dropping from 211 pounds to 155 pounds using a GLP-1 medication alongside daily hiking and resistance training. She quit the drug after six months but regained 20 pounds despite strict diet and exercise, concluding it is a lifetime commitment, much like blood pressure medication. On The Oprah Podcast and The View, Winfrey discussed overcoming shame from decades of public weight ridicule, including comedian jokes she once accepted as deserved. Co-authoring the book Enough with Yale endocrinologist Dr. Ania Jastreboff, she challenged myths of willpower, likening obesity to a brain-driven disease that silences food noise. Guest stories highlighted persistent shaming regardless of method, with Jastreboff urging focus on health over blame.Yet experts raise cautions. University of Cambridge research in Obesity Reviews warns that without nutrition guidance, users risk deficiencies in protein, vitamins, and minerals, plus muscle loss leading to fatigue or osteoporosis. UCLs Dr. Adrian Brown and colleagues recommend bariatric-style care, prioritizing nutrient-dense foods. George Mason Universitys Martin Binks calls for holistic strategies with dietitians and exercise support, noting uneven access due to cost.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Novo Nordisk's new drug CagriSema has outperformed Ozempic in a recent Phase III trial for type 2 diabetes patients, according to Clinical Trials Arena. In the REIMAGINE 2 study, CagriSema reduced HbA1c levels by 1.91 percentage points and achieved 14.2 percent weight loss after 68 weeks, compared to 1.76 percentage points and 10.2 percent with Ozempic. No weight loss plateau occurred with CagriSema, and 43 percent of patients lost at least 15 percent of their body weight. Martin Holst Lange, Novo Nordisk's executive vice president and chief scientific officer, stated that combining semaglutide and cagrilintide delivers superior blood glucose control and weight reduction.Researchers are urging a more holistic approach to weight loss amid the Ozempic era, as reported by Medical Xpress on February 3. Experts like Martin Binks and Raedeh Basiri from George Mason University note that GLP-1 drugs such as Ozempic cause rapid weight loss but can lead to nutrient deficiencies, muscle loss, and struggles without proper nutrition, exercise, and psychological support. Many patients receive only prescriptions without multidisciplinary care, and access remains limited by cost and insurance gaps. Binks predicts broader availability with upcoming pill forms.A study highlighted by Science Daily on January 29 warns of rapid weight regain after stopping drugs like Ozempic, with people regaining about 0.4 kilograms per month, often faster than with diet and exercise alone. Heart health and diabetes risk improvements also reverse quickly, emphasizing the need for long-term strategies beyond medication.Oprah Winfrey has shared her experiences with GLP-1 medications, similar to Ozempic, in recent interviews covered by AOL and other outlets. At 71, she regrets not using them sooner, saying they silenced the food noise in her head and helped her view obesity as a disease, not a personal failure. She gained 20 pounds after stopping briefly but now sees these drugs as a lifelong tool, like blood pressure medication, and encourages others without shame.These developments show evolving options and cautions in weight loss treatments. Listeners, thanks for tuning in, please subscribe, and remember, this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Oprah Winfrey has been candid this week about her ongoing use of GLP-1 medications like those containing semaglutide, the active ingredient in Ozempic, for weight management. In recent interviews promoting her new book Enough: Your Health, Your Weight, and What It's Like to be Free, co-authored with Yale professor Dr. Ania M. Jastreboff, she shared that she started these weekly injections in 2023 and views them as a lifelong tool, much like blood pressure medicine. Oprah told People magazine she feels no shame in relying on them, explaining that after stopping for six months to test her willpower, she regained 20 pounds despite strict dieting and exercise. She now believes obesity influences overeating through genetics and hormones, freeing her from self-blame after decades of public scrutiny and jokes about her weight.Social media buzzed with debate over her comments on The View, where she said obesity causes overeating rather than the reverse, a view some experts clarify starts with overeating leading to obesity, which then complicates appetite control via elevated hunger hormones. Still, Oprah emphasizes these drugs help by reducing hunger and slowing stomach emptying, as noted by Harvard Health.Meanwhile, regulators issued fresh guidance on GLP-1s this week. The UK's Medicines and Healthcare products Regulatory Agency updated advice for prescribers and patients on semaglutide products like Ozempic and Wegovy, highlighting a small risk of severe acute pancreatitis. They noted about 1.6 million adults in England, Wales, and Scotland used these for weight loss between early 2024 and early 2025, per University College London research. In Canada, generic semaglutide became possible after Novo Nordisk's data exclusivity expired on January 4, promising more affordable options soon.Long-term data reinforces their efficacy. The STEP 5 trial showed once-weekly semaglutide yielding 15.2 percent sustained weight loss at 104 weeks, with mild gastrointestinal side effects like nausea most common. Tirzepatide, a dual agonist, outperformed in the SURMOUNT trials with up to 25 percent loss over 88 weeks. Experts like Dr. Caroline Apovian from Harvard stress indefinite use for best results, alongside diet and exercise, while new oral versions and pipeline drugs like amycretin aim to improve access.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

The landscape of weight loss treatment in America is shifting dramatically as glucagon-like peptide-one receptor agonists, or GLP-1s, continue to dominate conversations about obesity management. According to a Pew Research Center report from January 2026, thirteen states now cover GLP-1s for obesity treatment under Medicaid, though this represents progress tempered by significant setbacks. California, New Hampshire, Pennsylvania, and South Carolina stopped covering these medications as of January first, citing rising costs that have strained state budgets. The medications, which include popular drugs like Ozempic and Wegovy, have seen explosive growth, with Novo Nordisk reporting thirty-one point one billion dollars in combined revenue from these three drugs in 2024, nearly triple the eleven point nine billion from 2022.Public awareness of these medications continues to surge. According to Pew Research data from early 2025, about fifty-three percent of Americans say they hear or read about Ozempic, Wegovy, and similar drugs extremely or very often. Yet Americans remain divided on appropriate use. While fifty-three percent of those familiar with these medications see them as good options for people with obesity or weight-related health conditions, only twelve percent view them as appropriate for people who simply want to lose weight without existing health issues.Oprah Winfrey has been particularly vocal about her GLP-1 journey, recently speaking with CBS about her experience with these medications. In an interview from January 12, 2026, the seventy-one-year-old media mogul described how the medication eliminated what she calls "food noise" within hours of her first dose. She expressed deep regret that she did not discover this treatment option in 2013, speaking emotionally about the wasted years of shame and sadness surrounding her weight struggles. Winfrey now views obesity as a disease rather than a personal failure, a perspective shift that has transformed her relationship with these medications. After taking herself off the drug for a year to prove she could manage without it, she gained twenty pounds and has since recommitted to the treatment, recognizing that like her blood pressure medication, these drugs represent a long-term management tool she needs to maintain her health.The first week of 2026 has highlighted the complex reality of weight loss medication access in America. While newer treatments continue to emerge and awareness spreads, insurance coverage remains inconsistent and often declining. The tension between rising demand, limited access through public programs, and growing pharmaceutical revenues underscores the ongoing challenges in making these transformative treatments available to all Americans who need them.Thanks for listening. Please subscribe and remember, this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot AI. We'll be back next week with more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Oprah Winfrey shared striking insights this week on her experience with Ozempic, a popular drug known as semaglutide for type two diabetes and weight management. On the Today Show on January 21, 2026, the media icon revealed she gained 20 pounds after stopping the medication for nearly a year. She wanted to prove she could maintain her weight through discipline alone, including hiking regularly and exercising up to two hours a day, six days a week. But the weight returned quickly, leading her to resume the injections. Oprah compared it to lifelong blood pressure medicine, saying she has proven to herself that she needs it. A new BMJ study mentioned in the discussion found that people quitting GLP-one drugs like Ozempic regain about four kilograms every month and can recover all lost weight within two years.This personal story aligns with warnings from experts this week. Doctor Andre Teixeira, a bariatric surgeon, told Scripps News that without lifestyle changes, most people regain 67 percent of their weight within two years after stopping these drugs. The medications slow digestion and reduce cravings, but effects fade 30 to 90 days after discontinuation, often worsening prior metabolic issues. Gina Leinninger, a physiology professor at Michigan State University, called them forever drugs in an MSUToday article, noting the body fights to defend higher weights once gained, making sustained loss challenging even with diet and exercise.Meanwhile, legal concerns mount over Ozempic side effects. Lawsuit Information Center reported on January 17, 2026, that Novo Nordisk faces potential mass torts in New Jersey for claims of gastroparesis, or stomach paralysis, and NAION, a vision loss condition. The GLP-one multidistrict litigation now includes over 3,000 cases, with predictions of high value for severe NAION injuries. Gastric emptying studies are key to proving these claims, as symptoms like nausea, vomiting, and bloating can persist without cure.These developments highlight Ozempic's dual role as a powerful weight loss tool and a medication demanding long-term commitment amid emerging risks.Thanks for tuning in, listeners. Please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Oprah Winfrey has been candid this week about her experiences with GLP-1 medications like Ozempic for weight loss. According to RadarOnline on January 16, she dropped about 50 pounds two and a half years ago after starting the drug but gained back 20 pounds when she stopped taking it after six months. She shared on The View and her podcast that she once blamed herself for her weight, feeling shame from constant food noise in her head, but now views obesity as a disease beyond personal control, much like addiction. Oprah explained that thin people simply do not think about food constantly, and the medication silenced that urge for her, even reducing her desire for alcohol like tequila.RadarOnline reports Oprah calling it a lifetime commitment, similar to blood pressure medicine, as stopping leads to regain despite diet and exercise. She told CBS News she is now down to 155 pounds from a default of 211, feeling in the best shape of her life at 71 through the drugs combined with daily hiking and resistance training. Oklahoma Magazine notes she has no shame in using GLP-1s, covers costs for friends, and stresses overeating does not cause obesity but the reverse, freeing her from self-blame.Experts echo this. Michigan State University Today featured physiologist Gina Leinninger this week, who calls GLP-1 drugs like Ozempic and Wegovy game-changers for obesity, mimicking hormones to curb hunger since the brain defends higher weights. She warns they are forever drugs, with effects reversing quickly upon stopping, and urges reserving them for those who need them amid shortages and high costs up to one thousand dollars monthly. Stony Brook Medicine on January 15 detailed how these injections or pills delay stomach emptying, leading to 15 percent average weight loss with semaglutide when paired with lifestyle changes, though side effects like nausea can be managed by eating smaller protein-rich meals slowly.A Los Angeles Times analysis on January 15 highlighted broader impacts, noting widespread use could save U.S. airlines over five hundred million dollars yearly in fuel from lighter passengers. Business Insider affirmed Oprah's influence persists, validating medical over willpower approaches.Thanks for tuning in, listeners, come back next week for more. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Health Canada approved the first glucagon-like peptide one daily pill, Rybelsus, on Monday for adults with type two diabetes who face high risks of heart disease. This semaglutide pill, made by the same company behind injectable Ozempic and Wegovy, aims to improve blood sugar levels alongside diet and exercise while cutting chances of heart attacks, strokes, or death from cardiovascular events. Company trials with over nine thousand six hundred fifty patients showed it lowered those risks compared to a placebo. Unlike prior GLP one drugs in Canada, all injectables until now, this offers a convenient oral option, though experts note it may need higher doses since stomach acids break down some of the peptide, making injections potentially more effective for weight loss.Recent studies highlight challenges with these medications. A review in the British Medical Journal, published this week, analyzed sixty-three trials involving more than nine thousand people and found users regain weight at about zero point four kilograms per month after stopping GLP one drugs, with heart benefits vanishing too. In the United States, the food and drug administration approved an oral Wegovy pill last month, now available for around one hundred forty-nine United States dollars monthly through places like Amazon Pharmacy.Oprah Winfrey, seventy-one, shared candid thoughts on GLP one medications this week during appearances on CBS Sunday Morning and The View. She called them a vital tool for managing obesity, a disease she now views without shame or self-blame. Winfrey said the constant food noise in her mind vanished hours after her first dose, freeing her from obsession despite still enjoying food. She regrets not discovering them in two thousand thirteen, lamenting wasted years of sadness, and admitted gaining twenty pounds in a year after stopping to test her willpower, proving to her it is a lifelong need like blood pressure medicine. Promoting her new book with doctor Ania Jastreboff, she stressed obesity causes overeating, not the reverse, and urged ending blame, even covering costs for friends who cannot afford it.Analysts at Jefferies noted on January twelfth that widespread use of weight loss drugs like Ozempic could save major United States airlines up to five hundred eighty million dollars in fuel this year, as lighter passengers cut jet fuel needs by up to one point five percent. In Canada, semaglutide patents expired this month, paving the way for cheaper generics to boost access.Thanks for tuning in, listeners, please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Recent research from Cornell University reveals that weight-loss drugs like Ozempic and Wegovy are significantly reducing how much Americans spend on food. According to the study published in the Journal of Marketing Research, households cut grocery spending by an average of 5.3 percent within six months of starting these GLP-1 receptor agonist medications, with higher-income families seeing drops over 8 percent. Fast-food and coffee shop spending fell by about 8 percent too. The biggest declines hit savory snacks, sweets, baked goods, and cookies, down around 10 percent, while yogurt and fresh fruit purchases rose modestly. Sylvia Hristakeva, an assistant professor of marketing at Cornell, noted that these changes persist for at least a year among ongoing users but fade after stopping.Oprah Winfrey shared her personal experiences with GLP-1 medications in recent interviews. Business Insider reports that the 71-year-old media icon regrets not discovering these drugs earlier, calling them a vital tool for managing obesity as a chronic disease. She described how the constant food noise in her head vanished within hours of her first dose, leaving her indifferent to food obsessions despite still enjoying it. Winfrey told CBS Sunday Morning she wept thinking of years wasted on shame, believing her struggles stemmed from personal failure rather than biology. After stopping for a year to test herself, she gained 20 pounds, proving to her that the medication is essential, much like blood pressure drugs.On NBC's Today show, Winfrey discussed side effects from her GLP-1 use while promoting her new book with Yale's Dr. Ania M. Jastreboff. She experienced constipation but no nausea or diarrhea, managing it by drinking a gallon of water daily before 4 p.m. to keep her kidneys happy. The book aims to shift views on obesity, comparing stigma around these drugs to past misconceptions about alcoholism.Experts predict further evolution for these treatments. Fox News Digital spoke with specialists forecasting 2026 shifts, including GLP-1s as multi-system metabolic modulators targeting heart, kidney, and liver health beyond just weight. Novo Nordisk launched a daily oral semaglutide pill nationwide on January 5, offering a convenient non-injection option. A new Oxford University study across 37 trials with over 9,000 adults found weight regain averages 0.4 kilograms per month after stopping these drugs.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Ozempic and similar glucagon like peptide 1 medicines remain at the center of the weight loss conversation this week, as new research and renewed celebrity attention highlight both their promise and their limits. According to a January report from the American Society for Metabolic and Bariatric Surgery, scientists reviewing records from more than fifty thousand patients found that people who had bariatric surgery lost about five times more weight over two years than those using weekly glucagon like peptide 1 medicines such as semaglutide, the active ingredient in Ozempic. The analysis, presented at the societys annual scientific meeting and summarized by Science Daily, showed surgery patients averaging roughly fifty eight pounds of weight loss, compared with about twelve pounds for people prescribed Ozempic or related drugs for at least six months. Even among those who stayed on these medicines continuously for a full year, average loss reached only about seven percent of body weight, much lower than the surgical group, underscoring how hard it is for many people to stay on these drugs over time because of cost, side effects, or supply issues. At the same time, obesity specialists quoted this week by Fox News Digital say they expect a major shift in how Ozempic style treatments are used. Rather than being seen only as weight loss shots, doctors are increasingly framing them as whole body metabolic medicines that can lower cardiovascular risk and protect the kidneys and liver, with next generation combinations already in development that may bring greater and more durable weight loss with easier dosing, including daily pills and, in trials, long lasting implants. Against this medical backdrop, Oprah Winfrey continues to shape how many listeners think about Ozempic and weight. In a new People magazine cover story highlighted by AOL in the last few days, she describes her decision to start a glucagon like peptide 1 medicine about two and a half years ago as part of accepting that she lives with the disease of obesity rather than a simple failure of discipline. She explains that understanding obesity as something rooted in genes and biology allowed her to stop blaming herself for decades of weight cycling. Oprah does not name a specific brand in that piece, but she speaks directly to people who see themselves in her story, saying that if obesity runs in your family, it is not your fault and that access to accurate information about medicines, lifestyle changes, and risks should guide decisions, not shame. She also notes that even with medication she still eats carefully and exercises most days, and she expects to remain on a glucagon like peptide 1 treatment long term. For listeners, the message from both the new data and Oprahs comments is that Ozempic and related medicines can be powerful tools, but they are not magic fixes and they work best as part of an ongoing plan that may include surgery, structured exercise, and long term medical follow up. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

This week, new research and policy news are reshaping the conversation around Ozempic and other weight loss drugs, while Oprah Winfrey continues to influence how many listeners think about these medications. On the scientific front, a major analysis presented by the American Society for Metabolic and Bariatric Surgery compared real world outcomes for more than fifty thousand people using glucagon like peptide one drugs such as semaglutide, the active ingredient in Ozempic, with those who underwent bariatric surgery. According to ScienceDaily, patients who had gastric bypass or sleeve gastrectomy lost about five times more weight over two years than those using weekly injections, averaging around fifty eight pounds lost with surgery versus about twelve pounds with the drugs. The study also found that many people stop taking medications like Ozempic within a year, limiting long term results and highlighting issues like side effects, costs, and difficulty staying on treatment consistently. At the same time, policymakers are trying to make these drugs easier to afford. The Arkansas Center for Health Improvement reports that the Trump administration has rolled out a new voluntary payment model called Balance, aimed at expanding access to glucagon like peptide one medicines for certain Medicare and Medicaid patients. Under this approach, federal health programs would negotiate lower prices with drug makers and pair coverage with lifestyle and nutrition support. Separate agreements announced earlier with makers of semaglutide and tirzepatide are expected to bring down monthly costs for public programs and some patients over the next few years, though many details and timelines are still evolving. Drug makers are also pushing to expand the ways people can take these medications. Gastroenterology Advisor reports that Novo Nordisk has just launched the first daily oral weight loss pill containing semaglutide nationwide, offering an alternative to injections for those who qualify for medical obesity treatment. For listeners, this means more choices but also more complexity, as they weigh injections versus pills, cost, availability, and how long they will need to stay on therapy. Against this fast moving backdrop, Oprah Winfrey continues to shape public attitudes toward drugs like Ozempic. In recent coverage from outlets such as People Magazine and New Beauty, revisited widely again this week as these new studies and policies emerged, Oprah describes glucagon like peptide one medication as a long term tool rather than a quick fix, saying it helped quiet the constant mental chatter around food and even reduced her desire for alcohol. She has emphasized that she no longer blames herself for decades of weight struggles and instead views obesity as a chronic condition that sometimes requires medical treatment plus healthy habits, not just willpower. Her message, resurfacing in commentary around the latest research, is that these medications can be powerful but work best when combined with lifestyle changes and realistic expectations about how much weight loss they can safely deliver and how long people may need to stay on them. For listeners trying to understand the latest Ozempic headlines, this week underscores three points. Surgery still delivers the biggest and most durable weight loss for severe obesity, new payment and pricing models may slowly improve access to glucagon like peptide one drugs, and high profile voices like Oprah are pushing the conversation toward seeing obesity as a medical disease that may require multiple tools rather than a personal failure. Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

The weight loss medication debate has taken a fascinating turn as public figures continue to grapple with the decision to use drugs like Ozempic and Wegovy. Oprah Winfrey, one of America's most influential personalities, has found herself at the center of this conversation, and her stance reveals the complex relationship many people have with these powerful pharmaceutical tools. For years, Oprah publicly resisted using Ozempic, stating that she felt taking the medication would be taking the easy way out. However, she later revealed that she had lost forty pounds using a weight loss medication, creating a significant shift in her public messaging that sparked considerable backlash from critics who pointed out this apparent contradiction to her earlier statements about the easy way out.The emergence of GLP-1 drugs like semaglutide, marketed as Ozempic, has fundamentally changed how we think about weight management. These medications work by suppressing appetite while you are taking them and stabilizing blood sugar levels. The science behind these drugs is compelling. A landmark clinical trial from 2021 published in the New England Journal of Medicine tested once weekly semaglutide at two point four milligrams in adults with overweight or obesity. Participants lost far more weight than those on placebo, achieving the kind of weight loss previously seen only after bariatric surgery. Beyond weight reduction, research from 2023 and 2024 found that semaglutide reduced major cardiovascular events including heart attack and stroke in people with overweight or obesity and existing heart disease, effectively moving the drug out of cosmetic territory and into life saving potential for specific patients.However, the medication comes with significant downsides that listeners should understand. Gastrointestinal side effects are not rare but rather expected. Nausea, vomiting, constipation and diarrhea affect most users, with higher doses associated with increased risks of these symptoms. These side effects represent the number one reason people discontinue the medication. Additionally, once patients stop taking the drug, hunger signals return to normal, metabolism shifts back, and many people regain some or most of the weight they lost. This is why doctors emphasize the importance of long term lifestyle changes alongside medication use.Other public figures have shared their experiences with these drugs. Elon Musk revealed using Wegovy specifically for weight loss and fitness benefits, while Tracy Morgan joked openly about being on Ozempic and losing weight like crazy. Amy Schumer admitted to trying Ozempic but quit because side effects made daily life unbearable. Sharon Osbourne publicly discussed losing too much weight on Ozempic and struggling to regain it. These varied experiences highlight that individual responses to GLP-1 medications differ significantly.The broader cultural moment surrounding Ozempic reflects how normalized GLP-1 culture has become in recent years. Social media has accelerated speculation about whether various celebrities use these drugs, with some attributing every photograph showing weight loss to semaglutide use. This tendency reveals an important problem with how we discuss body changes and medical treatments in the public sphere. Weight fluctuations at any age can result from exercise, hormones, stress, camera angles, health events, fashion and styling choices, none of which require a prescription.Ozempic remains neither a miracle nor a menace but rather a powerful medical tool that can change lives for better or worse depending on how and why it is used. The medication should only be prescribed after proper screening for heart, kidney and endocrine issues. Doctors warn against taking it before major events like weddings or holidays, obtaining it through questionable online pharmacies, or using it purely for cosmetic transformation. These drugs require genuine medical supervision and serious consideration.Thank you for tuning in to this episode. Please come back next week for more in depth coverage of health and wellness topics. Thanks for listening, please subscribe, and remember, this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In the past week, the conversation around weight loss medications, particularly Ozempic, has intensified following new statements from Oprah Winfrey. Oprah recently addressed her own experience with the drug, clarifying her previous comments and responding to public speculation. According to recent reports, Oprah revealed that she lost forty pounds using Ozempic, a medication originally developed for type two diabetes but now widely used off-label for weight loss. Her admission comes after months of public scrutiny and rumors about her sudden weight change, which some had speculated was due to the use of GLP-1 medications like Ozempic.Oprah’s comments mark a shift from her earlier stance, where she had described using such medications as taking the easy way out. In her latest remarks, she expressed regret for those words and apologized for suggesting that people should starve themselves to lose weight. She emphasized that her journey with weight loss has been complicated and that she now understands the value of medical interventions for those who struggle with obesity. Oprah’s openness has sparked renewed debate about the role of medications in weight management and the stigma often associated with their use.Public health experts have weighed in, noting that while Ozempic and similar drugs can be effective, they are not a one-size-fits-all solution. These medications work by mimicking a hormone that regulates appetite and blood sugar, leading to reduced hunger and gradual weight loss. However, they are not without risks and side effects, and their long-term impact is still being studied. Doctors caution that these drugs should be used under medical supervision and as part of a broader approach to health that includes diet, exercise, and behavioral changes.The discussion has also highlighted the broader cultural conversation about body image and the pressure to achieve rapid weight loss. Oprah’s experience underscores the challenges many face when trying to manage their weight in a society that often equates thinness with success. Her apology for past comments reflects a growing awareness that weight loss is a deeply personal journey and that judgment and shame are not helpful tools.In the past week, media coverage has focused on the implications of Oprah’s statements, with many listeners expressing relief that a prominent figure is speaking candidly about the realities of weight loss. The conversation continues to evolve as more people share their own experiences and as medical professionals provide guidance on the safe and effective use of medications like Ozempic.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Ozempic, the prescription drug originally developed to treat Type 2 diabetes, continues to generate headlines as one of the most discussed weight loss medications on the market. In the past week, the conversation has shifted back into public focus as new studies and high-profile personal stories further drive debate on its use and implications. According to Science Daily, researchers have underscored the impressive impact of GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro on significant weight loss. However, scientists highlight that there are still considerable unknowns when it comes to the long-term effects, especially as demand continues to surge among both diabetic patients and those seeking weight management solutions. They emphasize the critical need for more independent research to validate the safety and effectiveness of these drugs over time, cautioning against viewing them as a universal fix for weight issues.Amid the scientific scrutiny, public figures play a central role in shaping trends and personal attitudes toward weight loss medications. Oprah Winfrey’s statements and her journey with weight loss drugs have been at the forefront of news coverage this week. She spoke candidly in a recent interview cited by OK! magazine about her experiences with weight fluctuations and the intense shame she internalized for decades. Winfrey admitted that after years of public and private struggle, she finally decided to seek a medically supervised course for her health, incorporating a weight loss medication into her routine in combination with hiking, dietary discipline, and a structured daily routine. As reported, although she did not publicly name the drug she uses, her remarks align with the widespread awareness of Ozempic, which remains frequently referenced in mainstream media when discussing celebrity weight loss.Winfrey’s openness about her past resistance to medication due to feelings of inadequacy resonates with many. She acknowledged that she once felt compelled to prove she could lose weight through sheer willpower, rejecting medical intervention as a sign of failure. Her perspective shifted after recognizing that obesity is fundamentally a complex disease involving genetics and neurobiology. She now regards medically approved prescriptions as a legitimate tool, describing the medications as a “relief, redemption, and a gift.” Winfrey’s reflection provides an alternative narrative to years of celebrity culture that equated body shape with personal virtue or discipline, stating that she is finished with the cycle of self-blame and external judgment.The cultural impact of Oprah’s statements is amplified by the fact that, by her account, she has come to use these new medications largely to prevent the notorious “yo-yoing” phenomenon many people face with repeated weight loss and regain. Importantly, Oprah emphasizes that weight management is not about a number on a scale but about health, vitality, and quality of life. She continues to balance her use of the medicine with exercise and mindful eating, such as following Weight Watchers principles, hydrating adequately, and eating earlier in the day. Her story, widely covered by outlets including People magazine, has contributed to shifting the national conversation around both the legitimacy and the expectations of new weight management drugs.Meanwhile, the voice of the medical and scientific community remains cautious. They point out that, despite the clear short-term benefits observed in many users of Ozempic and similar drugs, long-term outcomes are unclear, and questions remain about side effects, sustainability, and the risk of weight regain if the drug is discontinued. As the number of people turning to Ozempic for weight loss continues to climb, especially in the wake of influential figures presenting medication as part of their success, researchers call for more systematic observation and independent study.In a recent personal milestone shared on social media, Oprah described completing a challenging hike she first attempted decades ago at a much higher weight, viewing the accomplishment as a powerful affirmation of her journey toward health more than any number on the scale. This symbolism, as reported in Parade magazine, captures a broader societal shift from focusing exclusively on weight to encompassing vitality, self-acceptance, and holistic wellness. With interest in Ozempic undiminished, stories like Oprah’s underscore the nuanced convergence of medicine, celebrity influence, and public health messaging at a time when demand for effective weight management solutions is higher than ever.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Ozempic continues to dominate weight loss conversations, with its effects and celebrity endorsements fueling public fascination over the past week. Headlines have focused on both the drug’s growing popularity and nuanced statements from influential figures like Oprah Winfrey. The mainstream press has highlighted new comments from Oprah Winfrey regarding her personal experience with weight loss medications. After persistent speculation about her noticeably slimmer appearance at public events such as The Color Purple premiere, Oprah confirmed in a People magazine interview that she does use a prescription weight loss drug as part of her overall health strategy. However, she declined to specify the exact medication, leaving open questions about whether Ozempic is part of her regimen. She was candid about her reliance on medication as a tool in her journey to avoid the familiar cycle of weight fluctuations, often referred to as yo-yo dieting. This marks a shift from previous remarks, when she publicly wrestled with the decision about whether to use drugs like Ozempic and Wegovy, feeling that they might constitute taking the easy way out. As reported by AOL, she admitted to initially refusing these medications but ultimately reached a decision to collaborate with her doctor for a medically supervised approach to weight management.This current news cycle illustrates how social attitudes toward Ozempic and similar drugs continue to evolve. The drug, originally developed for diabetes management, has seen off-label use expand dramatically as new research supports its effectiveness in achieving sustained weight loss. According to some healthcare experts cited in HELLO Magazine, there is increased awareness about the risks and benefits of these drugs, particularly in relation to long-term health outcomes. The celebrity debate now centers less on whether to use Ozempic and more on how to use it responsibly and transparently. Oprah’s stance is frequently spotlighted because her influence on health and wellness discussions is significant. Her openness about using prescription medication, balanced by her reluctance to name a specific drug, reflects a nuanced position that many people find relatable.Notably, this week’s reports emphasize that Oprah does not see medication as a standalone solution but rather as a complement to other healthy habits. She stressed that her weight management regimen includes active choices like healthy eating and regular physical activity, suggesting that medication alone cannot guarantee lasting results. HealthBanks reports that Oprah views weight loss drugs as a tool to be used “as I feel I need it” — not as a shortcut but as part of a broader, individualized plan. The importance of avoiding stigma is another major theme: both Oprah and other public figures are highlighting the need for empathy toward those who choose medical assistance, rejecting simplistic views about personal responsibility or willpower. This stance is echoed across Hollywood, as other celebrities confront speculation about their own experiences with Ozempic, often articulating that medication is one option among many. Some celebrities have denied ever using weight loss medications, stressing the value of healthy eating, exercise, and hard work. The conversation appears to be shifting away from moral judgments and toward understanding obesity and weight management as complex medical issues.Media coverage this week also reflects broader societal shifts. With Ozempic and similar drugs entering the mainstream, regulators and physicians are raising new concerns about access, proper supervision, and potential side effects if used without guidance. As more patients inquire about prescriptions, clinics and health authorities say they are monitoring for misuse and ensuring people understand both the benefits and the risks. In summary, over the last seven days, the discussion about Ozempic and weight loss has been shaped largely by celebrities like Oprah Winfrey, whose decisions resonate far beyond Hollywood. The message from Oprah and from current news sources is one of transparency, nuance, and empathy — emphasizing that successful weight management may require a range of approaches, from medical support to lifestyle changes, and that the best outcomes happen under proper medical supervision.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In the past week, breakthrough developments surrounding Ozempic and its use for weight loss have dominated health news, reflecting sweeping changes in both medical access and public perception. According to Popular Mechanics, Novo Nordisk, the pharmaceutical giant behind Ozempic and the similar injectable Wegovy, has just revealed the results of a major 71-week clinical study evaluating an oral pill form of semaglutide, the active ingredient in both Ozempic and Wegovy. This study, published in The New England Journal of Medicine, found that the daily pill achieved nearly the same results as the weekly injection, with participants losing an average of 16.6 percent of their body weight, far surpassing the 2.7 percent weight loss seen in the placebo group. About one third of those taking the pill lost more than 20 percent of their starting weight, signaling not just statistical significance but profound clinical impact. The trial also reported side effects consistent with earlier injectable versions, including increased incidences of nausea and vomiting, though these were not severe enough to derail the optimism surrounding the pill’s future.Compounding these scientific advancements, the White House this week announced successful negotiations with both Eli Lilly and Novo Nordisk to dramatically reduce the cost of GLP-1 receptor agonists—the drug class of Ozempic, Wegovy, and Zepbound—which many insurance providers had previously excluded or charged full price for. Now, eligible patients may see their out-of-pocket costs plummet from over one thousand dollars per month to a much more accessible fifty to three hundred fifty dollars depending on dosage and coverage. According to comments from Kim Fisher at the UC Davis Innovation Institute for Food and Health, these price adjustments are expected to drive a swift increase in demand and medication use, with around one in eight adult Americans having already tried some form of GLP-1 therapy.Despite the popularity and transformative outcomes touted by both consumers and medical professionals, Ozempic and related drugs are not without controversy. While these medications have reshaped the landscape for obesity and diabetes treatment, as UC Davis reports, emerging evidence indicates a need for caution and individualized care. Some patients experience notable gastrointestinal effects such as nausea and diarrhea, largely because GLP-1 drugs alter how the gut processes food and signal fullness to the brain. In addition, while fat loss can be dramatic, experts highlight that up to one quarter of the total weight lost may be from lean muscle, underscoring the importance of physical activity and adequate protein to preserve strength. Another concern echoed this week involves bone health, as rapid weight loss and restricted nutrition may inadvertently reduce bone density, especially in older adults and postmenopausal women. Leading researchers emphasize that a successful and safe weight loss journey with Ozempic demands precision nutrition, attentive exercise regimens, and regular monitoring to minimize health risks and maximize wellbeing.The intersection of celebrity culture with the Ozempic phenomenon also drew fresh attention over the past week, especially regarding Oprah Winfrey’s evolving relationship with the drug. Oprah, who has long shared her struggles with weight publicly, admitted in recent interviews that she initially resisted taking Ozempic, saying she felt it was the easy way out and preferred to focus on lifestyle change. According to AOL, she reflected on her internal conflict about using medical intervention for weight loss, underscoring how the rise of drugs like Ozempic has forced a cultural reckoning over what constitutes effort, discipline, and legitimacy in personal health. While some celebrity peers openly dismiss rumors or deny any use of weight loss drugs, Oprah’s decision to speak candidly about her hesitation and subsequent experiences gives voice to a wider conversation happening both in Hollywood and across the nation. As more public figures reveal their choices, the stigma of using medication to address chronic weight struggles may begin to dissipate, helping others seek support without shame.In summary, the past week has marked a pivotal moment in the ongoing Ozempic story. The introduction of a highly effective oral pill, substantial price cuts via government negotiation, and ongoing public debate about safety, efficacy, and cultural perceptions have all contributed to growing momentum. Now, as clinicians and patients alike look ahead to a future where advanced weight management tools are both more accessible and potentially safer to use, the importance of personalized guidance and health literacy has never been clearer.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Ozempic continues to spark headlines as its role in weight loss becomes more central to discussion in both medical circles and popular culture over the past week. Driven by ongoing demand and complex debate, the medication, originally developed for managing type two diabetes, is being increasingly prescribed as an aid for weight reduction. Recent news coverage demonstrates that the public conversation about Ozempic’s impact is not slowing down. One of the most prominent voices weighing in this week has been Oprah Winfrey, who has offered candid reflections on her own experiences with Ozempic and the accompanying social reactions.This week, Oprah Winfrey openly addressed her use of Ozempic, stating that the medication had been part of her recent weight loss journey. The disclosure provoked a surge of reaction, with many in the media and public responding to her admission. According to JB Press, Oprah was direct in acknowledging how Ozempic had contributed to her results and sincerely discussed the reasons behind her choice. She emphasized that her decision was informed not just by the desire for weight loss, but by a broader understanding of health, aging, and the pressures faced by individuals in the public eye. Oprah expressed that Ozempic helped her manage not only her physical appearance but also her relationship with food and ongoing health challenges.The admission generated considerable controversy, especially in social media circles and news outlets. AOL reports that Oprah faced criticism from some who accused her of taking what they described as the easy way out. Detractors argued that reliance on medication sidesteps the harder emotional and behavioral work of traditional weight loss approaches. Yet, others pointed out that access to new treatments like Ozempic can democratize health outcomes for people who have battled obesity and associated health issues for years. Notably, Oprah addressed the backlash with clarity, stating that individual health decisions are complex and personal, and that stigma can deter meaningful progress in addressing obesity.While much of the discussion this week has centered on celebrity use and cultural debate, medical professionals have continued to caution that Ozempic is not a substitute for healthy eating or exercise. They underscore that while it may curb appetite and support weight loss, it should be prescribed thoughtfully and monitored by a physician. New data has emerged suggesting that demand for Ozempic has increased during the past seven days, especially following endorsements by well-known personalities. This has prompted ongoing examination regarding accessibility, cost, and responsible use.The increased attention on Ozempic this week has also reignited questions about the long-term effects of its use. Medical experts, as quoted in several news sources, remind listeners that Ozempic is primarily intended for people with type two diabetes, and that off-label use must be scrutinized to prevent negative outcomes. They warn against seeking the medication without proper guidance and note that lifestyle change remains a crucial part of sustainable weight management. The FDA continues to evaluate the safety profile of these drugs as more data comes to light.Overall, the recent wave of coverage shows that Ozempic is at the heart of a rapidly evolving public conversation about medicine, body image, and social stigma. Oprah Winfrey’s openness this week has made a significant impact, both in encouraging honest dialogue and in prompting critical reflection about how we perceive health and beauty in the modern era. The question of whether medical intervention for weight loss constitutes an easy fix or an important tool remains active, and the story continues to evolve as more individuals and experts join the discussion.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Recent research has revealed that the heart health benefits of the weight loss drug Ozempic, which contains the active ingredient semaglutide, are not solely due to weight loss. A large study published in The Lancet and led by researchers at University College London analyzed data from more than seventeen thousand adults aged forty five and older who were overweight and had cardiovascular disease. The participants were randomly assigned to receive weekly injections of semaglutide or a placebo. The study found that semaglutide significantly reduced the risk of major cardiac events such as heart attacks, strokes, and cardiovascular deaths, regardless of how much weight each participant lost during the first four and a half months of treatment. This means that even people who lost little or no weight experienced similar heart protection as those who lost a substantial amount.The study also looked at the impact of waist circumference, which is a marker for visceral fat, and found that a reduction in waist size was linked to about one third of the heart benefits seen in patients taking semaglutide. However, the majority of the cardiovascular benefit was not explained by changes in weight or waist size alone. This suggests that semaglutide may have direct effects on the underlying causes of heart disease, beyond just helping people lose weight. Experts say this could mean the drug might be beneficial for patients who are not severely overweight, including those with BMIs in the normal range, although further research is needed to confirm this.Oprah Winfrey has recently spoken about her own experience with Ozempic, describing it as a tool she uses to manage her weight. She has emphasized that medication is not the only way to lose weight and that it should be seen as one option among many. Oprah has also discussed the broader cultural conversation around weight loss drugs, highlighting the need to address weight stigma and body shaming. Her openness has sparked a national dialogue about the role of prescription medications in weight management and the importance of focusing on overall health rather than just appearance.The findings from the latest research are prompting doctors and researchers to reconsider how they approach the treatment of obesity and heart disease. While Ozempic and similar drugs were originally developed for diabetes, their ability to protect the heart even without significant weight loss is a major development. This could lead to new treatment strategies for people at high risk of cardiovascular events, regardless of their body size. As the medical community continues to explore the full range of benefits and risks associated with these medications, the conversation around weight loss and heart health is becoming more nuanced and inclusive.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI